Log in to save to my catalogue

TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into...

TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3049862199

TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism

About this item

Full title

TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism

Publisher

England: BMJ Publishing Group Ltd and British Society of Gastroenterology

Journal title

Gut, 2024-12, Vol.73 (12), p.2012-2022

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd and British Society of Gastroenterology

More information

Scope and Contents

Contents

ObjectiveAchieving HBV cure will require novel combination therapies of direct-acting antivirals and immunomodulatory agents. In this context, the toll-like receptor 8 (TLR8) agonist selgantolimod (SLGN) has been investigated in preclinical models and clinical trials for chronic hepatitis B (CHB). However, little is known regarding its action on im...

Alternative Titles

Full title

TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_3049862199

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3049862199

Other Identifiers

ISSN

0017-5749,1468-3288

E-ISSN

1468-3288

DOI

10.1136/gutjnl-2023-331396

How to access this item